Search Results | Blood | American Society of Hematology

1-20 of 445

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Evaluation of the Fibrin Assay for Venous Thromboembolism Exclusion in Cancer Patients: Subanalysis of a Prospective Assessment (FSET STUDY)

Isabelle Mahe, MD PhD, Jean Chidiac, MD, Sadji Djennaoui, MD, Nicolas Javaud, MD PhD, Benjamin Planquette, MD PhD, Edith Peynaud-Debayle, MD, Laurent Sofiane Baccar, MD, Bénédicte Dumont, PhD, Guy Meyer, Geneviève Contant, PhD, Francois Depasse, PharmD, Virginie Siguret, PhD, Hélène Helfer, PhD

Blood (2019) 134 (Supplement_1): 3663.

DOI: https://doi.org/10.1182/blood-2019-124973

Published: 2019

Journal Articles

Use of Anticoagulants of Patients with Cancer-Associated Thrombosis Beyond 6 Months ; The Uscat Study, a 432-Patient Retrospective Non-Interventional Study

Isabelle Mahe, MD PhD, Ludovic Plaisance, MD, Céline Chapelle, Silvy Laporte, MS, PhD, Benjamin Planquette, MD PhD, Laurent Bertoletti, MD PhD, Jean Chidiac, MD, Francis Couturaud, MD PhD, Lionel Falchiero, MD, Nicolas Falvo, MD, Isild Mahé, Hélène Helfer, PhD, Guy Meyer

Blood (2019) 134 (Supplement_1): 3664.

DOI: https://doi.org/10.1182/blood-2019-124745

Published: 2019

Journal Articles

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Manoj P. Menon, MD, Victor A. Chow, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Andrei Shustov, MD, Stephen D. Smith, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Chaitra S. Ujjani, MD, Thomas S. Uldrick, MD MS, Edus H. Warren, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4733.

DOI: https://doi.org/10.1182/blood-2019-127505

Published: 2019

Journal Articles

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Patrizia Mondello, MD PhD MSc, Irene Dogliotti, MD, Jan-Paul Bohn, Federica Cavallo, Simone Ferrero, MD, Barbara Botto, Claudio Cerchione, MD PhD, Davide Nappi, Sonya De Lorenzo, Giovanni Martinelli, MD, Dominik Wolf, Univ. Prof. Dr., Giacomo Loseto, MD, Salvatore Cuzzocrea, MD PhD, Wolfgang Willenbacher, MD PhD, Michael Mian, MD

Blood (2019) 134 (Supplement_1): 1565.

DOI: https://doi.org/10.1182/blood-2019-128198

Published: 2019

Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD

Blood (2019) 134 (Supplement_1): 1536.

DOI: https://doi.org/10.1182/blood-2019-124515

Published: 2019

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

DOI: https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

Anthony K. N. Chan, PhD, Christopher D. Delaney, Lu Yang, PhD, Wen-Han Chang, PhD, Kazuya Miyashita, PhD, Qiao Liu, MD, Sheela Pangeni Pokharel, MSc, Scott A. Armstrong, MD PhD, Chun-Wei David Chen, PhD

Blood (2019) 134 (Supplement_1): 530.

DOI: https://doi.org/10.1182/blood-2019-131467

Published: 2019

Journal Articles

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Andrew Dunbar, MD, Kelly Bolton, MD PhD, Sean M. Devlin, PhD, Francisco Sanchez-Vega, PhD, Jianjiong Gao, PhD, Jodi V. Mones, MD, Jonathan M. Wills, BA, Daniel Kelly, MS, Mirko Farina, MD, Sirish Kishore, MD, Krishna Juluru, MD, Neil Iyengar, MD, David M. Hyman, MD, Ahmet Zehir, PhD, Wungki Park, MD, Alok A Khorana, MD, Gerald A. Soff, MD, Simon Mantha, MDMPH

Blood (2019) 134 (Supplement_1): 633.

DOI: https://doi.org/10.1182/blood-2019-124242

Published: 2019

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2019) 134 (Supplement_1): 781.

DOI: https://doi.org/10.1182/blood-2019-125204

Published: 2019

Journal Articles

Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy

Kyaw Zin Thein, MDMBBS, Lukman Tijani, MD, Thein H. Oo, MD

Blood (2019) 134 (Supplement_1): 3466.

DOI: https://doi.org/10.1182/blood-2019-128561

Published: 2019

Journal Articles

Severe Chronic Neutropenia in the Large Granular Lymphocyte Syndrome: Outcomes in Response to Granulocyte Colony Stimulating Factor (G-CSF) and Immunosuppressive Therapies

David C. Dale, MD, James A. Shannon, IV, Audrey Anna Bolyard, RN, BS, Jim Connelly, MD, Daniel C. Link, MD, Mary Ann Bonilla, MD, Peter E. Newburger, MD

Blood (2019) 134 (Supplement_1): 3589.

DOI: https://doi.org/10.1182/blood-2019-126181

Published: 2019

Journal Articles

Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

Shadi Swaidani, MD PhD, Joanna Roopkumar, MBBS, MPH, Young Jun-Shim, PhD, Cathy Charles, Slato Paul, Suman Kundu, MBA, Pauline Funchain, MD, Patricia Rayman, Paul G. Pavicic, C. Marcela Diaz-Montero, PhD, Alok A Khorana, MD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 3648.

DOI: https://doi.org/10.1182/blood-2019-130911

Published: 2019

Journal Articles

Incidence and Risk Factors of Arterial Thromboembolism in Non-Small Cell Lung Cancer

Avi Leader, MD, Oded Icht, MD, Erez Batat, Uri Rozovski, MD, Lilach Joseph, Tzippy Shochat, Daniel A Goldstein, MD, Elizabeth Dudnik, MD, Baruch Brenner, MD, Pia Raanani, MD, Galia Spectre, Hammerman Ariel, PhD, Alona Zer, MD

Blood (2019) 134 (Supplement_1): 3654.

DOI: https://doi.org/10.1182/blood-2019-128822

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

DOI: https://doi.org/10.1182/blood-2019-131231

Published: 2019

Journal Articles

Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms

Keertik Fulzele, PhD, Cristina Panaroni, PhD, Kenta Mukaihara, MD PhD, Tomoaki Mori, MD PhD, Shrikanta Chattopadhyay, MBBS, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 1802.

DOI: https://doi.org/10.1182/blood-2019-131213

Published: 2019

Journal Articles

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Lorena Fontan, PhD, John Hatcher, PhD, David Scott, Qi Qiao, Ilkay Us, Guangyan Du, Matthew Durant, Jimmy Wilson, Hao Wu, PhD, Nathanael Gray, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2073.

DOI: https://doi.org/10.1182/blood-2019-130666

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

DOI: https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD

Blood (2019) 134 (Supplement_1): 764.

DOI: https://doi.org/10.1182/blood-2019-124750

Published: 2019

Journal Articles

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Philip A. Thompson, MBBS, Michael J Keating, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Prithviraj Bose, MD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 358.

DOI: https://doi.org/10.1182/blood-2019-129230

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

DOI: https://doi.org/10.1182/blood-2019-132246

Published: 2019

2 3 4 5

NARROW

Evaluation of the Fibrin Assay for Venous Thromboembolism Exclusion in Cancer Patients: Subanalysis of a Prospective Assessment (FSET STUDY)

Use of Anticoagulants of Patients with Cancer-Associated Thrombosis Beyond 6 Months ; The Uscat Study, a 432-Patient Retrospective Non-Interventional Study

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy

Severe Chronic Neutropenia in the Large Granular Lymphocyte Syndrome: Outcomes in Response to Granulocyte Colony Stimulating Factor (G-CSF) and Immunosuppressive Therapies

Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

Incidence and Risk Factors of Arterial Thromboembolism in Non-Small Cell Lung Cancer

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only